Prosigna Assay for Treatment Decisions in Early Breast Cancer: A Decision Impact Study

Esin et al. (Mon,) studied this question.

www.synapsesocial.com/papers/68e590e0b6db64358752c12f — DOI: https://doi.org/10.3390/jcm13175328

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer· 2017 · 27 citations
2. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers· 2017 · 21 citations
3. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer· 2016 · 33 citations
4. Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer· 2005 · 572 citations
5. How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists· 2012 · 226 citations